Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.88 Average PT from Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have earned a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $16.88.

Several analysts have recently commented on FOLD shares. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Bank of America increased their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. raised their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th.

Insider Activity

In related news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $11.46, for a total value of $85,950.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $10,161,054.84. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 22,901 shares of company stock worth $259,863 over the last 90 days. 2.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in FOLD. OLD Second National Bank of Aurora bought a new position in Amicus Therapeutics during the third quarter valued at about $26,000. Hazlett Burt & Watson Inc. grew its stake in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares during the last quarter. Blue Trust Inc. raised its stake in Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI acquired a new stake in Amicus Therapeutics in the 3rd quarter worth $32,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Amicus Therapeutics during the third quarter valued at about $55,000.

Amicus Therapeutics Trading Up 0.5 %

Shares of Amicus Therapeutics stock opened at $9.41 on Wednesday. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The company’s 50-day simple moving average is $9.70 and its 200-day simple moving average is $10.53. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of -27.68, a price-to-earnings-growth ratio of 1.25 and a beta of 0.62. Amicus Therapeutics has a 52-week low of $8.78 and a 52-week high of $14.03.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.